KFDA approves Takedas Prucalopride capsules for metastatic colorectal cancer Approval granted for Takedas Prucalopride ...
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 V ...
Plus: Maura Healey meets with eds-and-meds leaders about threats to research funding; Takeda sends zebras flying at Celtics ...
US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...
January 24, 2025 Takeda-backed Ascentage Pharma aims to raise ... gets US approval Ascendis Pharma said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult ...
Yutaka Oba, 36, who heads Block 71 Japan, told The Straits Times that the goal is to create a start-up ecosystem connecting ...
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback